대한본초학회지 (The Korea Journal of Herbology)

  • 제29권4호
  • /
  • Pages.29-34
  • /
  • 2014
  • /
  • 1229-1765(pISSN)
  • /
  • 2288-7199(eISSN)
대한본초학회 (The Korea Association of Herbology)
권호 표지
DOI QR코드

DOI QR Code

Dextran sulfate sodium으로 유도된 궤양성 대장염에 대한 와송의 억제효과

The inhibitory effect of Orostachys japonicus on dextran sulfate sodium-induced colitis in mice

  • 명노일 (원광디지털대학교 한방건강학과)
  • Myung, Noh-Yil (Department of Oriental Medicine and Healthcare, Wonkwang Digital University)
  • 투고 : 2014.06.30
  • 심사 : 2014.07.14
  • 발행 : 2014.07.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : Ulcerative colitis (UC) is an inflammatory bowel disease, which is one of chronic gastrointestinal disorders. Orostachys japonicus (OJ) has been used as a traditional medicine for various diseases including gastric cancer, gastric ulcers and intoxication. However, the regulatory effect of OJ on intestinal inflammation has not been fully understood, yet. The aim of this study was to investigate the effect of OJ on dextran sulfate sodium (DSS)-induced colitis in mice. Methods : To ascertain the pharmacological effects of OJ, the colitis mice were induced by drinking water containing 5% DSS for 7 days. Mice were randomized into groups receiving OJ (100 mg/kg), sulfasalazine (150 mg/kg) as a positive control, or water as a negative control. We evaluated the effects of OJ on DSS-induced the clinical signs, measuring weight loss and colon length. In addition, the inhibitory effect of OJ on the tumor necrosis factor-${\alpha}$ (TNF-${\alpha}$) level was determined by enzyme-linked immunosorbent assay in colitis tissue. Results : The results indicated that mice treated with DSS showed remarkable clinical signs, including weight loss, and reduced colon length. However, treatment with OJ significantly improved the weight loss and DAI as clinical symptoms. Moreover, OJ reduced the TNF-${\alpha}$ levels in DSS-treated colon tissues. Conclusions : Collectively, the findings of this study provide us with novel insights into the pharmacological actions of OJ as a potential medicine for use in the treatment of ulcerative colitis.

키워드

참고문헌

  1. Bae KH. Illustrated Book of Health for Longevity. Seoul : Kyohaksa. 2003 : 180.
  2. Jung BS, Shin MK. Dictionary of the Medical Plants. Seoul : Younglimsa. 1990 : 600-1.
  3. Ryu DS, Kim SH, Kwon JH, Lee DS. Orostachys japonicus induces apoptosis and cell cycle arrest through the mitochondria-dependent apoptotic pathway in AGS human gastric cancer cells. Int J Oncol. 2014 ; 45(1) : 459-69. https://doi.org/10.3892/ijo.2014.2404
  4. Lee HS, Lee GS, Kim SH, Kim HK, Suk DH, Lee DS. Anti-oxidizing effect of the dichloromethane and hexane fractions from Orostachys japonicusin LPS-stimulated RAW 264.7 cells via upregulation of Nrf2 expression and activation of MAPK signaling pathway. BMB Rep. 2014 ; 47(2) : 98-103. https://doi.org/10.5483/BMBRep.2014.47.2.088
  5. Hyams JS. Inflammatory bowel disease. Pediatr Rev. 2000 ; 21 : 291-5. https://doi.org/10.1542/pir.21-9-291
  6. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease; the role of environmental factors. Autoimmun Rev. 2004 ; 3 : 394-400. https://doi.org/10.1016/j.autrev.2004.03.002
  7. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002 ; 15 : 79-94. https://doi.org/10.1128/CMR.15.1.79-94.2002
  8. Lichtenstein GR, Rutgeerts P. Inflamm Bowel Dis. 2010 ; 16(2) : 338-46. https://doi.org/10.1002/ibd.20997
  9. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev. 2004 ; 3(5) : 394-400. https://doi.org/10.1016/j.autrev.2004.03.002
  10. Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ. Disease-related expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010 ; 59(2) : 227-35. https://doi.org/10.1136/gut.2009.184176
  11. Medzhitov R, Janeway CA Jr. "Innate immunity: impact on the adaptive immune response". Curr Opin Immunol. 1997 ; 9(1) : 4-9. https://doi.org/10.1016/S0952-7915(97)80152-5
  12. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des. 2003 ; 9(14) : 1107-13. https://doi.org/10.2174/1381612033455035
  13. Zheng P, Niu FL, Liu WZ, Shi Y, Lu LG. Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats. World J Gastroenterol. 2005 ; 11(31) : 4912-5. https://doi.org/10.3748/wjg.v11.i31.4912
  14. Ishiguro K, Ando T, Maeda O, Hasegawa M, Kadomatsu K, Ohmiya N, Niwa Y, Xavier R, Goto H. Paeonol attenuates TNBS-induced colitis by inhibiting NF-B and STAT1 transactivation. Toxicol Appl Pharmacol. 2006 ; 217(1) : 35-42. https://doi.org/10.1016/j.taap.2006.07.002
  15. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. Novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990 ; 98(3) : 694-702. https://doi.org/10.1016/0016-5085(90)90290-H
  16. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002 ; 15(1) : 79-94. https://doi.org/10.1128/CMR.15.1.79-94.2002
  17. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993 ; 38(9) : 1722-34. https://doi.org/10.1007/BF01303184
  18. Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion. 2006 ; 73(1) : 67-76. https://doi.org/10.1159/000089781
  19. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000 ; 51 : 289-98. https://doi.org/10.1146/annurev.med.51.1.289
  20. Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005 ; 17 : 547-57 https://doi.org/10.1097/00042737-200505000-00012
  21. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA, Strom TB. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci. 1992 ; 37(6) : 818-26. https://doi.org/10.1007/BF01300378
  22. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998 ; 22(4) : 382-9. https://doi.org/10.1007/s002689900401